Interest of the Donor-specific Antibodies After Liver Transplantation
NCT ID: NCT03238443
Last Updated: 2021-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2016-02-16
2019-07-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary objective :
Study the anti-HLA antibodies frequency preformed before liver transplantation and the kinetic of appearance of DSA and de novo complement-binding anti-HLA antibodies after liver transplantation.
Secondary objective :
* Risk factor of de novo DSA appearance (Immunosuppressive therapy, liver aetiology)
* Impact of DSA on:
* Graft and patients survivals
* Onset of allograft rejection (acute, late-onset, chronic)
* Unexplained liver graft dysfunction
* Unexplained liver enzymes abnormalities
* Liver fibrosis development (liver stiffness study using fibroscan©)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Monocytic Expression of HLA-DR After Liver Transplantation
NCT03995537
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
NCT00638144
Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?
NCT06761209
Obstetrical History and Anti-HLA Antibodies Level
NCT06021925
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
NCT00867243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written consent by the patient or his/her legal representative (especially patient with hepatic encephalopathy).
* Patients with health insurance
Exclusion Criteria
* Pregnant women or during lactation.
* Patient under curatorship.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sébastien Dharancy, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU, Hôpital Claude Huriez
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-A00418-41
Identifier Type: OTHER
Identifier Source: secondary_id
2014_18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.